15 December 2023 The Directors Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Ave SYDNEY NSW 2000 Dear Directors Kazia Therapeutics Limited— Registration Statement on Form F-3 We have acted as Australian legal counsel to Kazia Therapeutics Limited ACN 063 259 754 (Company), a public company limited by shares incorporated under the laws of the Commonwealth of Australia, in connection with its filing with the U.S. Securities and Exchange Commission (Commission) of a registration statement on Form F-3 under the U.S. Securities Act of 1933, as amended (Securities Act). The Registration Statement relates to the resale from time to time by the selling shareholder, including its transferees, donees, pledgees or successors-in-interest (Selling Shareholder) identified in the preliminary prospectus contained in the Registration Statement (Preliminary Prospectus) of up to 591,697 American Depositary Shares (ADSs), each representing ten fully paid ordinary shares in the capital of the Company (Shares). The ADSs covered by the Registration Statement are issuable upon the conversion of the Convertible Promissory Note (Note), dated as of 23 October 2023, issued by the Company to the Selling Shareholder pursuant to the Securities Purchase Agreement dated as of 23 October 2023 entered into by and between the Company and the Selling Shareholder (Securities Purchase Agreement). 1. Documents examined 1.1 For the purposes of this opinion, we have examined and relied on copies of the following documents: (a) the Registration Statement; (b) the Preliminary Prospectus; (c) the Securities Purchase Agreement; (d) the Note; and (e) the Constitution of the Company (Constitution). |